You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
远大医药(00512.HK)达成两份协议共涉资650万美元 丰富集团高创新性及高壁垒性产品管线
阿思达克 12-09 18:04
远大医药(00512.HK)公布,集团之联营公司Sirtex为丰富集团高创新性和高壁垒性产品管线,近期达成数宗交易及合作。

首先,与Nanospectra签订战略投资协议。据此,Sirtex牵头对Nanospectra进行了股权投资,以约150万美元认购Nanospectra首轮约6%的B-1类优先股及有权任命一名董事会成员。同时双方亦约定,Sirtex在一定期限内获得Nanospectra在精准抗肿瘤介入领域中用於实体肿瘤消融的全球创新医疗器械产品AuroLase在欧洲及亚洲地区的相关授权的独家优先谈判权,以及未来当Nanospectra拟转让控股权时享有独家优先谈判权。

此外,与BlackSwan签订股份收购协议,据此Sirtex将以约500万美元收购Black Swan约12.5%的股本权益,并可以选择以约定价格购买公司剩余股份。此外,Sirtex亦有权任命一位董事会观察员。

BlackSwan核心产品LavaTM为一款精准血管介入领域的全球创新的医疗器械,於2020 年9月获得美国食品药品管理局(FDA)的临床试验器械豁免(IDE)批准开展临床试验。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account